Marabelle A - Search Results

1

Immune checkpoint modulation for non-small cell lung cancer.

Soria JC, Marabelle A, Brahmer JR, Gettinger S. Soria JC, et al. Among authors: marabelle a. Clin Cancer Res. 2015 May 15;21(10):2256-62. doi: 10.1158/1078-0432.CCR-14-2959. Clin Cancer Res. 2015. PMID: 25979932

2

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.

Marabelle A, Kohrt H, Levy R. Marabelle A, et al. Clin Cancer Res. 2013 Oct 1;19(19):5261-3. doi: 10.1158/1078-0432.CCR-13-1923. Epub 2013 Aug 21. Clin Cancer Res. 2013. PMID: 23965900 Free PMC article.

3

Intratumoral immunization: a new paradigm for cancer therapy.

Marabelle A, Kohrt H, Caux C, Levy R. Marabelle A, et al. Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116. Clin Cancer Res. 2014. PMID: 24691639 Free PMC article.

4

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.

Chester C, Marabelle A, Houot R, Kohrt HE. Chester C, et al. Among authors: marabelle a. Curr Opin Immunol. 2015 Apr;33:1-8. doi: 10.1016/j.coi.2014.12.010. Epub 2015 Jan 7. Curr Opin Immunol. 2015. PMID: 25576932 Review.

5

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A. Shekarian T, et al. Among authors: marabelle a. Mutagenesis. 2015 Mar;30(2):205-11. doi: 10.1093/mutage/geu073. Mutagenesis. 2015. PMID: 25688113 Review.

6

Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.

Marabelle A, Gray J. Marabelle A, et al. Pediatr Blood Cancer. 2015 Aug;62(8):1317-25. doi: 10.1002/pbc.25508. Epub 2015 Mar 21. Pediatr Blood Cancer. 2015. PMID: 25808079 Review.

7

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Houot R, Schultz LM, Marabelle A, Kohrt H. Houot R, et al. Among authors: marabelle a. Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190. Cancer Immunol Res. 2015. PMID: 26438444 Review.

8

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.

Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Postel-Vinay S, et al. Among authors: marabelle a. Ann Oncol. 2016 Feb;27(2):214-24. doi: 10.1093/annonc/mdv550. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578728 Free article. Review.

9

Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer.

Chaput N, Marabelle A. Chaput N, et al. Among authors: marabelle a. Eur Respir J. 2015 Dec;46(6):1541-3. doi: 10.1183/13993003.01595-2015. Eur Respir J. 2015. PMID: 26621880 Free article. No abstract available.

10

Rationale for anti-OX40 cancer immunotherapy.

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Among authors: marabelle a. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters